![Magnetic resonance imaging (MRI) of the brain, brain tumor](https://www.ivybraintumorcenter.org/wp-content/uploads/2020/05/Press-Release-New-Trials-2000x600.jpg)
NIRAPARIB FOR NEWLY DIAGNOSED GLIOBLASTOMA
About the Glioblastoma
clinical trial
The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0 clinical trial to evaluate niraparib, a novel targeted therapy, in patients with newly diagnosed glioblastoma.
The goal of this Phase 0 study is to confirm that niraparib is capable of crossing the blood-brain barrier. Patients with positive results may advance to an expansion phase that combines therapeutic dosing of niraparib in combination with standard-of-care fractionated radiotherapy.
The expansion phase of this study will examine progression-free survival and monitor safety and tolerability of niraparib in combination with radiation.
- PARP (poly ADP ribose polymerase) is a protein that plays an important role in cell survival response to DNA damage.
- Niraparib (the treatment agent) is an oral, highly selective PARP inhibitor that blocks the tumor cell survival response.
- Niraparib is approved by the FDA for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
Glioblastoma Trial Details
Recruiting
Niraparib
Newly Diagnosed Glioblastoma
24 Participants
![Patient and doctor reviewing chart](https://www.ivybraintumorcenter.org/wp-content/uploads/2019/10/3-GBM-hexagon-cutout.png)
You may be eligible if:
- You are 18 years or older
- You have a suspected newly diagnosed glioblastoma
- You plan on following the standard treatment regimen, including surgical resection and radiation
View all eligibility criteria by visiting ClinicalTrials.gov or call 602-406-8605 to speak with a patient navigator.
Phase 0 Clinical Trial: How it works
![Icon of Brain Tumor Patient](https://www.ivybraintumorcenter.org/wp-content/uploads/2020/06/How-it-works_1@4x-257x300.png)
Once enrolled, a patient receives a short exposure to the experimental therapy days before a planned operation to remove their tumor.
![Glioblastoma Tumor Illustration](https://www.ivybraintumorcenter.org/wp-content/uploads/2020/06/How-it-works_2@4x-300x300.png)
This exposure is enough that when we remove the tumor, our team of experts can answer an important question: Did the treatment penetrate the tumor?
![Combination Therapy for Gliboblastoma](https://www.ivybraintumorcenter.org/wp-content/uploads/2020/06/How-it-works_3@4x-300x300.png)
If the drug penetrates the tumor at sufficient levels, the patient may move forward with receiving the treatment in combination with fractionated radiotherapy in the therapeutic expansion phase.
![Stopwatch Timer](https://www.ivybraintumorcenter.org/wp-content/uploads/2020/06/How-it-works_4@4x-300x300.png)
Alternatively, if the treatment has no effect on the tumor, the patient can enroll in another clinical trial without losing time or receiving ineffective treatment.
Am I Eligible?
Submit a free trial screening request today to learn if you may qualify for a clinical trial or talk to an Ivy Navigator by calling 602-406-8605.